{
    "id": 32626,
    "fullName": "B2M V69Wfs*34",
    "impact": "frameshift",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "B2M V69Wfs*34 indicates a shift in the reading frame starting at amino acid 69 and terminating 34 residues downstream causing a premature truncation of the 119 amino acid B2m protein (UniProt.org). V69Wfs*34, combined with S16Afs*27, demonstrates a loss of B2m protein expression via immunohistochemistry in a patient sample (PMID: 31008436), but has not been biochemically characterized and therefore, its effect on B2m protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 567,
        "geneSymbol": "B2M",
        "terms": [
            "B2M",
            "IMD43"
        ]
    },
    "variant": "V69Wfs*34",
    "createDate": "02/20/2020",
    "updateDate": "03/31/2020",
    "referenceTranscriptCoordinates": {
        "id": 188033,
        "transcript": "NM_004048",
        "gDna": "chr15:g.44715560delG",
        "cDna": "c.205delG",
        "protein": "p.V69Wfs*34",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20553,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient with high levels of microsatellite instability (MSI-high), B2M V69Wfs*34, and B2M L15fs*41 demonstrated a partial response when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35226,
                "profileName": "B2M L15fs B2M V69Wfs*34 MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20554,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient with high levels of microsatellite instability (MSI-high), B2M V69Wfs*34, and B2M T93Lfs*10 demonstrated a partial response when treated with a PD-L1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35227,
                "profileName": "B2M V69Wfs*34 B2M T93Lfs*10 MSI high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20557,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient with high levels of microsatellite instability (MSI high), B2M S16Afs*27, and B2M V69Wfs*34 demonstrated stable disease when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35230,
                "profileName": "B2M S16Afs*27 B2M V69Wfs*34 MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35216,
            "profileName": "B2M V69Wfs*34",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35226,
            "profileName": "B2M L15fs B2M V69Wfs*34 MSI high",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35227,
            "profileName": "B2M V69Wfs*34 B2M T93Lfs*10 MSI high",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35230,
            "profileName": "B2M S16Afs*27 B2M V69Wfs*34 MSI high",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188033,
            "transcript": "NM_004048",
            "gDna": "chr15:g.44715560delG",
            "cDna": "c.205delG",
            "protein": "p.V69Wfs*34",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188034,
            "transcript": "XM_005254549",
            "gDna": "chr15:g.44715560delG",
            "cDna": "c.205delG",
            "protein": "p.V69Wfs*34",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}